Limited independent evidence: only two independent sources cover this company. The score may change as more evidence appears.
Smith & Nephew is a London-headquartered medical technology manufacturer founded in 1856, employing 11,000 people globally. It designs, manufactures and distributes surgical products, wound care, orthopaedic reconstruction, trauma devices, and advanced wound bioactives across 90+ countries.
Mid-cap healthcare equipment supplier with diversified geographic footprint.
Head office United KingdomStaff ~17,500Revenue ~$5.8BWebsite ↗
Smith & Nephew reports genuine 63% absolute emissions cuts (Scope 1+2) and 59% Scope 3 reductions since 2021, backed by third-party verification. Energy transition is real but hampered by reliance on unbundled renewable energy certificates. Nature impact, water stewardship, and SBTi validation remain underdeveloped.
Smith & Nephew scores 53/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Scores are free. Companies can never pay for anything about their own score. Last verified October 2026.
That places Smith & Nephew joint 87th of 934 companies scored, and 1st of 22 in Healthcare / Pharmaceuticals.
Strongest on Carbon Footprint: Operations and Emissions Trajectory (8/10, 8/10). Weakest on Nature & Biodiversity Impact and Water Impact (3/10, 4/10).
For each question that lost points, the evidence our public rubric looks for that we didn't find.
A score changes when the evidence does. We use new published evidence at the next rescore. Anyone can send us new evidence, free. How to send it.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleSmith & Nephew's score has moved from 51 to 53 across 2 recorded reviews, up 2 points.
Aggregator-citation sweep: broker citations replaced with the primary disclosures they mirror, re-scored through the guarded pipeline under pinned code 9196601.
Initial public score 51 (publish-draft)
8 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
38% of them were published by Smith & Nephew itself; the rest come from independent sources.
“In 2024, the total market-based Scope 1 and Scope 2 GHG emissions footprint was 24,662 tonnes of CO2e.”
“Data independently assured by ERM CVS; more details and the full assurance report are available in the 2024 Sustainability Report on pages 46–47.”
“Smith+Nephew received an A rating in the assessment, which evaluates corporate supply chain engagement practices on climate issues.”
“We are developing our Scope 3 emissions reduction roadmap in preparation for submitting this to the Science Based Target Initiative (SBTi) for validation.”
“we are mindful of the importance of biodiversity, particularly in some of the countries in which we operate including Costa Rica and Malaysia.”
“environmental violation $12,500 1 — Smith & Nephew Inc. — EPA — 2025”
“Smith & Nephew Inc., agreed to pay a $16.8 million fine to settle parallel criminal charges announced by the U.S. Department of Justice.”
“The 2024 Annual Report on Form 20-F was filed with the SEC earlier today.”
If you believe a source has been misread or a newer version exists, submit a challenge.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Send new evidence, free
Scored low because little is published? Publish what you do and send us the link, free. If it holds up, your score changes, and the change is logged on your page.
How to send evidence →Put your score on your website, free
It shows the current score and links to this page, so it changes when the score does.
Track this score
Bidding for a public contract? Check if you need a Carbon Reduction Plan, free →
Free, independent, every source shown. Send it to any buyer who asks about your sustainability.
Smith & Nephew is the highest-scoring healthcare / pharmaceuticals company we've rated.
Among the 22 major healthcare / pharmaceuticals brands we've scored, Smith & Nephew sits 1st of 22.
Smith & Nephew leads its sector. These are the next 3 down.
Novartis cut its emissions to 4.36 MtCO2e in 2025, with Scope 1 and 2 down 45% and Scope 3 down 17% against 2022, under SBTi-validated targets for net zero by 2040.
See the breakdown →Nemera's total footprint has risen for two years, to 126,000 tCO2e in 2025, after falling from its 2019 level.
See the breakdown →GSK has credible climate infrastructure: verified Scope 1&2 data, SBTi-validated net-zero to 2045, and sector-leading nature disclosures.
See the breakdown →One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
We'll send one email to confirm. No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
Find your page and claim it, free →Scores are free. Companies can never pay for anything about their own score.